These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36535060)

  • 21. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome.
    Porter CK; Cash BD; Pimentel M; Akinseye A; Riddle MS
    BMC Gastroenterol; 2012 May; 12():55. PubMed ID: 22639930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of geographic distributions of Irritable Bowel Syndrome with Inflammatory Bowel Disease fail to support common evolutionary roots: Irritable Bowel Syndrome and Inflammatory Bowel Diseases are not related by evolution.
    Szilagyi A; Xue X
    Med Hypotheses; 2018 Jan; 110():31-37. PubMed ID: 29317064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
    Wellens J; Colombel JF; Satsangi JJ; Wong SY
    J Crohns Colitis; 2021 Aug; 15(8):1376-1386. PubMed ID: 33721882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
    Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stigmatization toward irritable bowel syndrome and inflammatory bowel disease in an online cohort.
    Taft TH; Bedell A; Naftaly J; Keefer L
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27501483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.
    Macaluso FS; Principi M; Facciotti F; Contaldo A; Todeschini A; Saibeni S; Bezzio C; Castiglione F; Nardone OM; Spagnuolo R; Fantini MC; Riguccio G; Caprioli F; Viganò C; Felice C; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Mannino M; Rizzo G; Orlando A;
    Dig Liver Dis; 2023 Feb; 55(2):154-159. PubMed ID: 36127228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
    Halpin SJ; Ford AC
    Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease.
    Elkharsawi A; Arnim UV; Schmelz R; Sander C; Stallmach A; Teich N; Walldorf J; Reuken PA
    Z Gastroenterol; 2022 Jan; 60(1):77-80. PubMed ID: 35042256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
    Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F
    Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Principi M; Macaluso FS; Todeschini A; Facciotti F; Contaldo A; Castiglione F; Nardone OM; Spagnuolo R; Doldo P; Riguccio G; Conforti FS; Viganò C; Ascolani M; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Caprioli F; Mannino M; Rizzo G; Orlando A;
    Eur J Gastroenterol Hepatol; 2023 Jun; 35(6):629-634. PubMed ID: 37115976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and Inflammatory Bowel Disease.
    Summa KC; Hanauer SB
    Gastroenterol Clin North Am; 2023 Mar; 52(1):103-113. PubMed ID: 36813419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.
    Berrill JW; Green JT; Hood K; Campbell AK
    Aliment Pharmacol Ther; 2013 Jul; 38(1):44-51. PubMed ID: 23668698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease.
    Xu AM; Li D; Ebinger JE; Mengesha E; Elyanow R; Gittelman RM; Chapman H; Joung S; Botwin GJ; Pozdnyakova V; Debbas P; Mujukian A; Prostko JC; Frias EC; Stewart JL; Horizon AA; Merin N; Sobhani K; Figueiredo JC; Cheng S; Kaplan IM; McGovern DPB; Merchant A; Melmed GY; Braun J
    Front Immunol; 2022; 13():880190. PubMed ID: 35464463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.